Evidence map›Paper›PMID 31737188›Full record

ArticleAmerican journal of translational research2019

Pterostilbene attenuates amyloid-β induced neurotoxicity with regulating PDE4A-CREB-BDNF pathway.

Jiao Meng, Yuhua Chen, Fangfang Bi, Hua Li, Cuicui Chang, Wei Liu

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Molecules (Basel, Switzerland) · 2023
    Article
  5. Review
  6. CircAXL Knockdown Alleviates AβNeurochemical research · 2022
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jiao MengCentral Laboratory of Medicine School, Xi'an Peihua University Xi'an 710100, China.
Yuhua ChenCentral Laboratory of Medicine School, Xi'an Peihua University Xi'an 710100, China.
Fangfang BiCentral Laboratory of Medicine School, Xi'an Peihua University Xi'an 710100, China.
Hua LiDepartment of Medical Science Research Center, Shaanxi Fourth People's Hospital Xi'an 710143, China.
Cuicui ChangCentral Laboratory of Medicine School, Xi'an Peihua University Xi'an 710100, China.
Wei LiuDepartment of Medical Science Research Center, Shaanxi Fourth People's Hospital Xi'an 710143, China.
The Fourth People's Hospital · CNXi'an Peihua University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid-β (Aβ) is considered partially responsible for cognitive dysfunction in Alzheimer's disease (AD). Resveratrol is known as an anti-neurotoxicity potential natural product, however low blood-brain-barrier (BBB) permissibility and low oral-bioavailability (OB) are the main limitations on its clinical potential. In this study, we illustrated that Pterostilbene (PTS), a kind of resveratrol analog which showed higher scores on BBB and OB, could overcome Aβ-induced neurotoxicity

Indexed as

Alzheimer’s diseaseamyloid-βmemory deficitPDE4APterostilbene

Identifiers

PMID31737188
PMCPMC6834512
OpenAlexW3000617737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.